

TEW

1615

Patent

Attorney Docket No. 1017751-000030



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop Amendment

In re Patent Application of

Bruno Criere et al.

Application No.: 10/030,262

Filing Date: April 17, 2002

Title: PHARMACEUTICAL COMPOSITION CONTAINING FENOFIBRATE AND THE PREPARATION METHOD

Group Art Unit: 1615

Examiner: LAKSHMI SARADA CHANNAVAJJA

Confirmation No.: 8894

AMENDMENT/REPLY TRANSMITTAL LETTER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Enclosed is a reply for the above-identified patent application.

☐ A Petition for Extension of Time is also enclosed.

☐ Terminal Disclaimer(s) and the ☐ \$65.00 (2814) ☐ \$130.00 (1814) fee per Disclaimer due under 37 C.F.R. § 1.20(d) are also enclosed.

☐ Also enclosed is/are \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

☐ Small entity status is hereby claimed.

☐ Applicant(s) requests continued examination under 37 C.F.R. § 1.114 and enclose the ☐ \$395.00 (2801) ☐ \$790.00 (1801) fee due under 37 C.F.R. § 1.17(e).

☐ Applicant(s) requests that any previously unentered after final amendments not be entered. Continued examination is requested based on the enclosed documents identified above.

☐ Applicant(s) previously submitted \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_ on \_\_\_\_\_  
for which continued examination is requested.

☐ Applicant(s) requests suspension of action by the Office until at least \_\_\_\_\_, which does not exceed three months from the filing of this RCE, in accordance with 37 C.F.R. § 1.103(c). The required fee under 37 C.F.R. § 1.17(i) is enclosed.

☐ A Request for Entry and Consideration of Submission under 37 C.F.R. § 1.129(a) (1809/2809) is also enclosed.

- ☒ No additional claim fee is required.
- ☐ An additional claim fee is required, and is calculated as shown below.

AMENDED CLAIMS					
	No. of Claims	Highest No. of Claims Previously Paid For	Extra Claims	Rate	Additional Fee
Total Claims	34	MINUS 47 =	0	x \$50.00 (1202) =	\$ 0.00
Independent Claims	2	MINUS 3 =	0	x \$200.00 (1201) =	\$ 0.00
If Amendment adds multiple dependent claims, add \$360.00 (1203)					
Total Claim Amendment Fee					\$ 0.00
<input type="checkbox"/> Small Entity Status claimed - subtract 50% of Total Claim Amendment Fee					\$ 0.00
<b>TOTAL ADDITIONAL CLAIM FEE DUE FOR THIS AMENDMENT</b>					<b>\$ 0.00</b>

- ☐ A check in the amount of \_\_\_\_\_ is enclosed for the fee due.
- ☐ Charge \_\_\_\_\_ to Deposit Account No. 02-4800.
- ☐ Charge \_\_\_\_\_ to credit card. Form PTO-2038 is attached.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL PC

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Date: April 13, 2006

By

  
Brian P. O'Shaughnessy  
Registration No. 32,747

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

Bruno Criere et al.

Application No.: 10/030,262

Filed: April 17, 2002

For: PHARMACEUTICAL  
COMPOSITION CONTAINING  
FENOFIBRATE AND THE  
PREPARATION METHOD



**Mail Stop Amendment**

Group Art Unit: 1615

Examiner: LAKSHMI SARADA  
CHANNAVAJJALA

Confirmation No.: 8894

**SUBSTITUTE RESPONSE UNDER 37 CFR 1.111**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Substitute Response revokes and replaces the "Amendment" filed April 11, 2006 in response to the Office Action dated March 14, 2006.

Boyer's methacrylic polymer matrix is formulated and applied as an alcohol solution. Thus, this Substitute Response more accurately characterizes the Boyer solution of a water-soluble (hydrophilic) binder as an alcohol – rather than an aqueous – solution (p. 9); and likewise removes reference to "moisture" in reference to "processing steps to minimize exposure of the microcrystalline fenofibrate to alcohol...." (p. 10). The Remarks also further distinguish over Boyer, e.g., in reference to claim 21 (p. 9).